aibio
Debt Financing ·
ICON plc issues $2.15 billion of senior unsecured notes
The notes mature in 2029, 2031 and 2036 and carry rates of 5.064%, 5.421% and 5.995%. Proceeds repaid term loans, a bridge facility and 2027 secured notes.
ICLR ICON PLC
ICON (ICLR) news
Latest ICON news
- Debt Financing
ICON plc subsidiary prices senior notes to repay bridge and term loans
ICON plc said its subsidiary priced three series of senior unsecured notes. Proceeds are meant to repay its bridge facility, senior secured term loans and 2027 notes.
What ICON does
ICON plc is a contract research organization founded in Dublin, Ireland, in 1990, providing outsourced development and services to pharmaceutical, biotechnology, medical device and government and public health organizations. Its service offering includes clinical development across all phases (Phases I-IV), peri and post approval work, data solutions, and site and patient access services. Its functional outsourcing and full-service and functional service partnerships extend the clinical offering to customers. Its laboratory services include bio-analytical, biomarker, vaccine, good manufacturing practice (GMP) and central laboratory testing. Acquisitions cited in the filing include KCR S.A., a CRO offering full service and functional services provision, HumanFirst, Inc., a life sciences technology company, BioTel Research, LLC, which provided medical imaging and cardiac safety monitoring services, and Oncacare Limited, a network of oncology research sites that recruit patients. ICON says it has approximately 40,100 employees and relationships with a majority of the world's top pharmaceutical and biotech companies. It describes itself as a company that aims to accelerate the development of customers' drugs and devices.
| Product or program | What it is | Stage |
|---|---|---|
| Clinical development services | Clinical trial services across Phases I-IV, peri and post approval, and patient access | |
| Laboratory services | Bio-analytical, biomarker, vaccine, GMP and central laboratory testing | |
| Functional service partnerships | Full-service and functional outsourcing for customers |
ICON annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | $229.3 million | $739.1 million |
| Cash from operations | $1.04 billion | $1.29 billion |
| Cash and equivalents | $647.3 million | $538.8 million |
| Short-term investments | $0 | $0 |
Questions about ICON
What is the ticker symbol of ICON?
ICON PLC trades under the ticker ICLR on NASDAQ.
Where is ICON listed?
ICON PLC is listed on NASDAQ.
Which country or territory is ICON listed under?
Our directory records ICON PLC under United States.
Does aibio.space cover ICON?
aibio.space lists ICON PLC among 2,820 public biotech companies and publishes its news here as stories appear.
What does ICON develop?
ICON plc is a contract research organization founded in Dublin, Ireland, in 1990, providing outsourced development and services to pharmaceutical, biotechnology, medical device and government and public health organizations. Its service offering includes clinical development across all phases (Phases I-IV), peri and post approval work, data solutions, and site and patient access services.
What is Clinical development services from ICON?
Clinical development services: Clinical trial services across Phases I-IV, peri and post approval, and patient access
What is Laboratory services from ICON?
Laboratory services: Bio-analytical, biomarker, vaccine, GMP and central laboratory testing
Is ICON profitable?
ICON PLC reported net income of $229.3 million for the fiscal year ended Dec 31, 2025, and generated $1.04 billion of cash from operations, per its annual report to the SEC.
How much cash does ICON have?
$809.0 million in cash at Sep 30, 2026, per its 6-K.
What is the latest ICON (ICLR) stock news?
Our latest story on ICON, dated Aug 18, 2026: "ICON plc issues $2.15 billion of senior unsecured notes". The notes mature in 2029, 2031 and 2036 and carry rates of 5.064%, 5.421% and 5.995%. Proceeds repaid term loans, a bridge facility and 2027 secured notes. Source.
Does ICON have debt, a term loan or convertible notes?
Our latest debt story, dated Aug 18, 2026: "ICON plc issues $2.15 billion of senior unsecured notes". The notes mature in 2029, 2031 and 2036 and carry rates of 5.064%, 5.421% and 5.995%. Proceeds repaid term loans, a bridge facility and 2027 secured notes. Source.
How can I follow ICON (ICLR) news?
Press Follow on this page to add ICON to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming ICON so far, in Debt Financing.
Investor discussion: ICON
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
Listing details
- Company
- ICON PLC
- Ticker
- ICLR
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction